AbstractIntrahepaticcholangiocarcinoma(iCCA)isamolecularlyheterogeneoushepatobiliaryneoplasmwithpoorprognosisandlimitedtherapeuticoptions.Theincidenceofthisneoplasmisgrowingglobally.OnethirdofiCCAtumorsareamenabletosurgicalresection,butmostcasesarediagnosedatadvancedstageswithchemotherapyastheonlyestablishedstandardofpractice.Nomoleculartherapiesarecurrentlyavailableforthetreatmentofthisneoplasm.ThepoorunderstandingofthebiologyofiCCAandthelackofknownoncogenicaddictionloopshashinderedthedevelopmentofeffectivetargetedtherapies.StudieswithsophisticatedanimalmodelsdefinedIDHmutationasthefirstgatekeeperinthecarcinogenicprocessandledtothediscoveryofstrikingalternativecellularorigins.RNA-andexome-sequencingtechnologiesrevealedthepresenceofrecurrentnovelfusionevents(FGFR2andROS1fusions)andsomaticmutationsinmetabolic(IDH1/2)andchromatin-remodelinggenes(ARID1A,BAP1).TheselatestadvancementsalongwithknownmutationsinKRAS/BRAF/EGFRand11q13high-levelamplificationhavecontributedtoabetterunderstandingofthelandscapeofmolecularalterationsiniCCA.Morethanclinicaltrialstestingmoleculartherapiesaloneorin北京哪家治白癜风好北京哪个治白癜风医院最好
